This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Veeva Systems (VEEV) Stock Moves -1.09%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $281.11, denoting a -1.09% move from the preceding trading day.
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
by Zacks Equity Research
VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.
Here's Why Veeva Systems (VEEV) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wall Street Analysts See Veeva (VEEV) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
by Indrajit Bandyopadhyay
OPRX's subscription shift, DAAP platform, and HCP-DTC reach suggest a moat is forming-but is it built to last?
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
by Zacks Equity Research
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Veeva (VEEV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Veeva Systems (VEEV) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Veeva Systems (VEEV) reached $291.25 at the closing of the latest trading day, reflecting a +1.83% change compared to its last close.
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
by Harshit Gupta
VEEV stock climbs 36% YTD as it accelerates its shift off Salesforce, betting on Vault to power future growth in life sciences.
Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
by Zacks Equity Research
LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-market.
Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know
by Zacks Equity Research
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy?
by Harshit Gupta
VEEV's split from Salesforce sets the stage for a high-stakes CRM showdown as both firms double down on life sciences innovation.
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
by Zacks Equity Research
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
by Zacks Equity Research
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
by Zacks Equity Research
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Veeva Systems (VEEV) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Veeva Systems (VEEV) reached $276.46 at the closing of the latest trading day, reflecting a -2.13% change compared to its last close.
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
by Zacks Equity Research
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
Veeva Systems' Vault CRM Momentum Builds With Top Biopharma Adoptions
by Harshit Gupta
VEEV sees rising Vault CRM adoption among top biopharma firms, driven by new features, fueling customer migration and growth.
Should You Invest in Veeva (VEEV) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
by Urmimala Biswas
AI momentum and rising demand for digital care put Zacks Medical Info Systems industry stocks like VEEV, TXG and IMDX in focus despite new tariff headwinds.
Why Veeva Systems (VEEV) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veeva Systems (VEEV) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $275.89, denoting a -2.04% move from the preceding trading day.
Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock
by Zacks Equity Research
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.